Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Autor: Cahn, PE, Cassetti, I, Losso, M, Bloch, MT, Roth, N, McMahon, J, Moore, RJ, Smith, D, Clumeck, N, Vanderkerckhove, L, Vandercam, B, Moutschen, M, Baril, J, Conway, B, Smaill, F, Smith, GHR, Rachlis, A, Walmsley, SL, Perez, C, Wolff, M, Lasso, MF, Chahin, CE, Velez, JD, Sussmann, O, Reynes, J, Katlama, C, Yazdanpanah, Y, Ferret, S, Durant, J, Duvivier, C, Poizot-Martin, I, Ajana, F, Rockstroh, JK, Faetkanheuer, G, Esser, S, Jaeger, H, Degen, O, Bickel, M, Bogner, J, Arasteh, K, Hartl, H, Stoehr, A, Rojas, EM, Arathoon, E, Gonzalez, LD, Mejia, CR, Shahar, E, Turner, D, Levy, I, Sthoeger, Z, Elinav, H, Gori, A, Monforte, A D'Arminio, Di Perri, G, Lazzarin, A, Rizzardini, G, Antinori, A, Celesia, BM, Maggiolo, F, Chow, TS, Lee, CKC, Azwa, R Iskandar Shah Raja, Mustafa, M, Oyanguren, M, Castillo, RA, Hercilla, L, Echiverri, C, Maltez, F, da Cunha, JG Saraiva, Neves, I, Teofilo, E, Serrao, R, Nagimova, F, Khaertynova, I, Orlova-Morozova, E, Voronin, E, Sotnikov, V, Yakovlev, AA, Zakharova, NG, Tsybakova, OA, Botes, ME, Mohapi, L, Kaplan, R, Rassool, MS, Arribas, JR, Gatell, JM, Negredo, E, Ortega, E, Troya, J, Berenguer, J, Aguirrebengoa, K, Antela, A, Calmy, A, Cavassini, M, Rauch, A, Stoeckle, M, Sheng, WH, Lin, HH, Tsai, HC, Changpradub, D, Avihingsanon, A, Kiertiburanakul, S, Ratanasuwan, W, Nelson, MR, Clarke, A, Ustianowski, A, Winston, A, Johnson, MA, Asmuth, DM, Cade, J, Gallant, JE, Ruane, PJ, Kumar, PN, Luque, AE, Panther, L, Tashima, KT, Ward, D, Berger, DS, Dietz, CA, Fichtenbaum, C, Gupta, S, Mullane, KM, Novak, RM, Sweet, DE, Crofoot, GE, Hagins, DP, Lewis, ST, McDonald, CK, DeJesus, E, Sloan, L, Prelutsky, DJ, Rondon, JC, Henn, S, Scarsella, AJ, Morales, JO, Ramirez, Santiago, L, Zorrilla, CD, Saag, MS, Hsiao, CB, Cahn, Pedro, Kaplan, Richard, Sax, Paul E, Squires, Kathleen, Molina, Jean-Michel, Avihingsanon, Anchalee, Ratanasuwan, Winai, Rojas, Evelyn, Rassool, Mohammed, Bloch, Mark, Vandekerckhove, Linos, Ruane, Peter, Yazdanpanah, Yazdan, Katlama, Christine, Xu, Xia, Rodgers, Anthony, East, Lilly, Wenning, Larissa, Rawlins, Sandy, Homony, Brenda, Sklar, Peter, Nguyen, Bach-Yen, Leavitt, Randi, Teppler, Hedy

Publikováno v: In The Lancet HIV November 2017 4(11):e486-e494

Overview of HIV-related lipodystrophy

Autor: Rossouw, TM, Botes, ME, Conradie, F

Publikováno v: Southern African Journal of HIV Medicine, Vol 14, Iss 1, Pp 29-33 (2013)
Southern African Journal of HIV Medicine; Vol 14, No 1 (2013)

Lipodystrophy is a well-recognised adverse effect of HIV and antiretroviral therapy, with certain antiretrovirals, specifically thymidine analogues, implicated in the aetiology and pathogenesis. Lipodystrophy is often accompanied by metabolic complic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::201a5e605d27f5cf372afd7e9ab7746d
https://sajhivmed.org.za/index.php/hivmed/article/view/100

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

Autor: Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM

Publikováno v: International Journal of Epidemiology; Feb2012, Vol. 41 Issue 1, p43-54, 12p

The prophylaxis of opportunistic infections in HIV-infected adults

Autor: Botes, ME, Levay, PF

Publikováno v: South African Family Practice; May 2004, Vol. 46 Issue: 4 p41-46, 6p